NIH: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R21) [PD-16-036]


This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes. To accomplish this, methods that evaluate cardiac risk prior to treatment and integrate evidence-based cancer treatment regimens with screening, diagnostic, and/or management strategies are sought. Research applications should focus on mitigation/management of adverse effects associated with anti-cancer treatments including: cytotoxic chemotherapies, targeted agents, immunomodulatory therapies and radiation (that occur during cancer treatment and/or long-term survivorship) as defined by cardiac specific common terminology criteria for adverse events (CTCAE).

 
Dates
Posted: November 17, 2015
Opened: January 16, 2016
Expires: January 8, 2019
 
For more information and to apply, go to http://grants.nih.gov/grants/guide/pa-files/PA-16-036.html